Literature DB >> 4209057

Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.

H B Hawley, R M Lewis, D R Swartz, D W Gump.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4209057

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN： 0011-393X


× No keyword cloud information.
  6 in total

1.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 3.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.

Authors:  A J Martin; C A Smalley; R H George; D E Healing; C M Anderson
Journal:  Arch Dis Child       Date:  1980-08       Impact factor: 3.791

5.  Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.

Authors:  U Paporisz; H G Posselt; R Wönne; W Ristow; D Röser; H Knothe; S W Bender
Journal:  Eur J Pediatr       Date:  1979-04-03       Impact factor: 3.183

6.  Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.

Authors:  J R Rodríguez; C H Ramírez-Ronda; M Nevárez
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.